I am a
Home I AM A Search Login

Papers of the Week

2022 Apr 02

Cancer Chemother Pharmacol

Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study.


T'jollyn H, Ackaert O, Chien C, Lopez-Gitlitz A, McCarthy S, Ruixo C P, Karsh L, Chi K, Chowdhury S, Ruixo J-J P, Agarwal N
Cancer Chemother Pharmacol. 2022 Apr 02.
PMID: 35366072.


Apalutamide plus androgen-deprivation therapy (ADT) has been approved for treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) based on data from phase 3 TITAN study. This analysis was conducted to describe pharmacokinetics of apalutamide and N-desmethyl-apalutamide and explore relationships between apalutamide exposure and selected clinical efficacy and safety observations.